• Users Online: 1499
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2020  |  Volume : 36  |  Issue : 2  |  Page : 146-150

A clinical study on risk behaviors and seroprevalence of HIV, hepatitis B, and hepatitis C among injection drug users on opioid substitution therapy: An observational study


Department of Psychiatry, Government Medical College, Srinagar, Jammu and Kashmir, India

Correspondence Address:
Dr. Aaliya Khanam
Department of Psychiatry, Government Medical College, Srinagar - 190 003, Jammu and Kashmir
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijsp.ijsp_70_19

Rights and Permissions

Introduction: Hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV infection among IDUs is an emerging trend. Opioid substitution therapy (OST) is an evidence-based treatment for opiate-dependent clients that replaces illicit drug use with medically prescribed, orally administered opiates such as buprenorphine. The objective of this study was to determine the sociodemographic variables; seroprevalence of HIV, hepatitis B, and hepatitis C; associated risk behaviors; comorbid substance use pattern; and psychiatric comorbidity among injection drug users (IDUs). Methods: A total of 57 IDUs aged between 18 and 60 years who attended the OST center during 4 months period of a government medical college in North India were included in the study. Results: All of the IDUs were males with a mean age of 26.55 ± 7.26 years. The mean dose of buprenorphine used for the substitution was 6.24 ± 2.4/day at the start of the therapy. Most of the patients were unemployed, with a maximum of them studied up to high school level. The most common substance abuse among IDU users was tobacco 47 (82.46%), followed by Cannabis 23 (40.35%). High-risk behavior found among OST clients was sharing needles (29.82%), unprotected sexual intercourse (12.28%), and sexual intercourse with multiple partners (3.51%). HCV testing showed positive among 9 (15.78%) clients. Conclusion: Oral substitution with buprenorphine is an effective harm reduction strategy for preventing HCV, HBV, and HIV among IDUs. Buprenorphine is a safe compound, with minimal side effects and minimal chances of overdoses.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed269    
    Printed22    
    Emailed0    
    PDF Downloaded47    
    Comments [Add]    

Recommend this journal